« Return to News | Awards & Advancement

Tim Mayleben named president and CEO of Esperion Therapeutics

Friday, January 4, 2013 01:56 PM

Esperion Therapeutics, a developer of small molecule therapies for the treatment of cardiometabolic disorders, has named Tim Mayleben as the new president and CEO of the company. Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, will become executive chairman and chief scientific officer.

Most recently, Mayleben served as president and CEO at Aastrom Biosciences. Previously, he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors; president, COO and a director of NightHawk Radiology; and COO and CFO of the original Esperion Therapeutics, which Newton also founded.

While at Esperion, Mayleben has raised more than $200 million in venture and institutional equity capital and negotiated the sale of Esperion to Pfizer for $1.3 billion in February 2004.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.